Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Penumbra, Inc. Common Stock (NY:PEN)

280.68 +5.36 (+1.95%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Penumbra, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Garmin Posts Better-Than-Expected Results, Joins SolarEdge Technologies, Compass, Appian And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Profit Machine Penumbra Surges On Solid Fourth-Quarter Beat, But Guidance Lags
The company easily beat fourth-quarter expectations. But there was one drawback in its report. 
Via Investor's Business Daily
Penumbra’s (NYSE:PEN) Q4 Sales Beat Estimates
Medical device company Penumbra (NYSE:PEN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 10.8% year on year to $315.5 million. On the other hand, the company’s... 
Via StockStory
Topics Earnings
Exposures Financial
Penumbra (PEN) Reports Q4: Everything You Need To Know Ahead Of Earnings
Medical device company Penumbra (NYSE:PEN) will be reporting earnings tomorrow afternoon. Here’s what you need to know. 
Via StockStory
10 Analysts Assess Penumbra: What You Need To Know
Via Benzinga
Peering Into Penumbra's Recent Short Interest
Via Benzinga
(PEN) - Analyzing Penumbra's Short Interest
Via Benzinga
Earnings Scheduled For February 18, 2025
Via Benzinga
Price Over Earnings Overview: Penumbra
Via Benzinga
12 Analysts Assess Penumbra: What You Need To Know
Via Benzinga
Artivion (NYSE:AORT) Q3 Earnings: Leading The Medical Devices & Supplies - Cardiology, Neurology, Vascular Pack
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the medical devices & supplies - cardiology, neurology, vascular stocks, including Artivion (NYSE:AORT) and its peers. 
Via StockStory
Unpacking Q3 Earnings: ICU Medical (NASDAQ:ICUI) In The Context Of Other Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including... 
Via StockStory
Spotting Winners: Penumbra (NYSE:PEN) And Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks In Q3
Looking back on medical devices & supplies - cardiology, neurology, vascular stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Penumbra (NYSE:PEN) and its peers. 
Via StockStory
Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q3 Teardown: Merit Medical Systems (NASDAQ:MMSI) Vs The Rest
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including Merit Medical Systems... 
Via StockStory
(PEN) - Analyzing Penumbra's Short Interest
Via Benzinga
Breaking Down Penumbra: 11 Analysts Share Their Views
Via Benzinga
This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Inspire Medical's Sleep Innovations Driving Big Gains
Inspire Medical, which makes innovative apnea relief devices, hit a key performance benchmark as its Relative Strength Rating jumped to 81. 
Via Investor's Business Daily
UniFirst, Getty Images, Shutterstock And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Inari Medical Catapults 30% On Rumored Stryker Takeover
Inari is best-known for its series of catheter-like devices that remove blood clots. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
How Is The Market Feeling About Penumbra?
Via Benzinga
Key Takeaways From Penumbra Analyst Ratings
Via Benzinga
Looking Into Penumbra's Recent Short Interest
Via Benzinga
Penumbra Is Poised For Growth As Blood Clot Awareness Rises: Analyst
Oppenheimer predicts growth for Penumbra Inc in MT market. Analyst initiates coverage with Outperform rating and $275 target price. 
Via Benzinga
This Elastic Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Why Penumbra Stock Zoomed 4% Higher Today
The latest news from the lab, plus an analyst's bullish move, combined to put some zip in the company's shares. 
Via The Motley Fool
Critical Insights From Penumbra Analyst Ratings: What You Need To Know
Via Benzinga
Peering Into Penumbra's Recent Short Interest
Via Benzinga
Why NYSE:PEN Is a Standout High-Growth Stock in a Consolidation Phase.
PENUMBRA INC (NYSE:PEN)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.